Sales and EBITDA rose significantly in H1 2026, driven by Specialty Chemicals, with net income and EPS up 14% year-over-year. Major investments in production capacity and a new U.S. site support growth, and full-year guidance is confirmed despite global uncertainties.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.